ReviewExpert review of respiratory medicine2011
Carbon nanotubes as delivery systems for respiratory disease: do the dangers outweigh the potential benefits?
Review in Expert review of respiratory medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Nanodrug Delivery Systems for Lower Respiratory Infections: Pulmonary Targeting, Anti-Infective Applications, and Translational Challenges.International journal of nanomedicine · 2026Review
- Treatment of lung diseasesMaterials today. Bio · 2025Review
- Toward clinical translation of carbon nanomaterials in anticancer drug delivery: the need for standardisation.Beilstein journal of nanotechnology · 2025Article
- Carbon Nanotube Immunotoxicity in Alveolar Epithelial Type II Cells Is Mediated by Physical Contact-Independent Cell-Cell Interaction with Macrophages as Demonstrated in an Optimized Air-Liquid Interface (ALI) Coculture Model.Nanomaterials (Basel, Switzerland) · 2024Article
- Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery.Journal of nanobiotechnology · 2022Review
- Innate but Not Adaptive Immunity Regulates Lung Recovery from Chronic Exposure to Graphene Oxide Nanosheets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.Future medicinal chemistry · 2022Review
- Susceptibility Factors in Chronic Lung Inflammatory Responses to Engineered Nanomaterials.International journal of molecular sciences · 2020Review
- A Weigh-in-Motion Characterization Algorithm for Smart Pavements Based on Conductive Cementitious Materials.Sensors (Basel, Switzerland) · 2020Article
- The Applications of Carbon Nanotubes in the Diagnosis and Treatment of Lung Cancer: A Critical Review.International journal of nanomedicine · 2020Review
- Carbon nanotubes: Evaluation of toxicity at biointerfaces.Journal of pharmaceutical analysis · 2019Review
- Article
- Carbon Nanotubes and Chronic Granulomatous Disease.Nanomaterials (Basel, Switzerland) · 2014Article
- Carbon nanotube-induced pulmonary granulomatous disease: Twist1 and alveolar macrophage M1 activation.International journal of molecular sciences · 2013Article
- Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases.Drug delivery and translational research · 2013Article
- PEGylated single-walled carbon nanotubes as nanocarriers for cyclosporin A delivery.AAPS PharmSciTech · 2013Article
- Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer.Lung Cancer (Auckland, N.Z.) · 2013Review
- Citrullination as early-stage indicator of cell response to single-walled carbon nanotubes.Scientific reports · 2013Article
- Innate Immune Responses to Nanoparticle Exposure in the Lung.Journal of environmental immunology and toxicologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Nanoparticle drug-delivery systems offer the potential for improved efficacy of treatment, and yet there are also potential risks associated with these novel therapeutic strategies. An attractive property of carbon nanotubes (CNTs) is that the tube- or fiber-like structure allows for extensive functionalization and loading of cargo. However, a large body of evidence indicates that CNTs may have adverse effects if used in drug delivery as they have been shown to cause pulmonary fibrosis and exacerbate lung disease in rodents with pre-existing lung diseases. Major factors that cause these toxic effects are the high aspect ratio, durability and residual metal content that generate reactive oxygen species. Therefore, careful consideration should be given to the possibility that lung inflammation or fibrosis could be significant side effects caused by a CNT-based drug-delivery system, thereby outweighing any potential beneficial effects of therapeutic treatment. However, functionalization of CNTs to modulate aspect ratio, biodegradability and to remove residual metals could allow for safe design of CNTs for use in drug delivery in certain circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.